Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Diabetes Mellitus, Type 1 ≥21 and <65 years old. 2. Clinical diagnosis of type 1 diabetes mellitus. For an individual to be enrolled at least one criterion from each list must be met. o for documented hyperglycemia (at least 1 must be met): i. Fasting glucose ≥126 mg/dL confirmed ii. Two-hour Oral Glucose Tolerance Test (OGTT) glucose ≥200 mg/dL confirmed iii. HbA1c ≥6.5% documented confirmed iv. Random glucose ≥200 mg/dL with symptoms v. No data at diagnosis is available but the participant has a convincing history of hyperglycemia consistent with diabetes o for requiring insulin at diagnosis (1 must be met): i. Participant required insulin at diagnosis and continually thereafter ii. Participant did not start insulin at diagnosis but upon investigator review likely needed insulin (significant hyperglycemia that did not respond to oral agents) and did require insulin eventually and used continually iii. Participant did not start insulin at diagnosis but continued to be hyperglycemic, had positive islet cell antibodies consistent with latent autoimmune diabetes in adults (LADA) and did require insulin eventually and used continually 3. Use of an insulin pump to treat his/her diabetes for at least 1 year. 4. Familiarity with a bolus calculator with the current insulin pump with pre-defined parameters for carbohydrate (CHO) ratio, insulin sensitivity factor (ISF), target glucose and active insulin. 5. HbA1c 6.5-9% as measured with DCA2000 or equivalent device. 6. Not currently known to be pregnant, breast feeding, or intending to become pregnant (females). 7. Demonstration of proper mental status and cognition for the study. 8. Willingness to avoid consumption of acetaminophen-containing products during the study interventions involving CGM use. 9. Willingness to refrain from strenuous exercise for 2 days prior to admission. Non-strenuous walks of less than 15 minutes around the guest house will be permitted during the study. 10. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, have stability on the medication for at least 2 months prior to enrollment in the study. 11. Normal renal function (determined utilizing the comprehensive metabolic panel at screening with the Modification of Diet in Renal Disease (MDRD) formula and defined by estimated Glomerular Filtration Rate (eGFR) ≥60 ml/min/1.73 m2  Known hypersensitivity to pramlintide or any of its components, including metacresol. 2. Severe hypoglycemia resulting in seizure, loss of consciousness, or diabetic ketoacidosis (DKA) within the 12 months prior to enrollment. 3. Pregnancy; breast feeding, or intention of becoming pregnant. 4. Uncontrolled arterial hypertension (Resting diastolic blood pressure >90 mmHg and/or systolic blood pressure >160 mmHg). 5. Conditions which may increase the risks associated with possible hypoglycemia, such as any active cardiac disorder/arrhythmia, uncontrolled coronary artery disease during the previous year (e.g. history of myocardial infarction, acute coronary syndrome, therapeutic coronary intervention, coronary bypass or stenting procedure, stable or unstable angina, episode of chest pain of cardiac etiology with documented electrocardiogram (EKG) changes, or positive stress test or catheterization with coronary blockages >50%), congestive heart failure, history of cerebrovascular event, seizure disorder, syncope, adrenal insufficiency, neurologic disease or atrial fibrillation. 6. Self-reported hypoglycemia unawareness. 7. History of a systemic or deep tissue infection with methicillin-resistant staph aureus or Candida albicans. 8. Use of a device that may pose electromagnetic compatibility issues and/or radiofrequency interference with the CGM (implantable cardioverter-defibrillator, electronic pacemaker, neurostimulator, intrathecal pump, and cochlear implants). 9. Anticoagulant therapy other than aspirin. 10. Medical condition requiring use of an acetaminophen-containing medication that cannot be withheld for the study admissions. 11. Psychiatric disorders that would interfere with study tasks (e.g. inpatient psychiatric treatment within 6 months prior to enrollment). 12. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. 13. Known current or recent alcohol or drug abuse. 14. Medical conditions that would make operating a CGM, the DiAs cell phone or insulin pump difficult (e.g. blindness, severe arthritis, immobility). 15. Any skin condition that prevents sensor or pump placement on the abdomen or arm (e.g. bad sunburn, pre-existing dermatitis, intertrigo, psoriasis, extensive scarring, cellulitis). 16. In adherence with the One Touch Ultra 2 User Guide, subjects with hematocrit levels less than 30% and above 55% will be excluded. 17. Impaired hepatic function measured as alanine aminotransferase or aspartate aminotransferase ≥three times the upper reference limit. 18. Abnormal liver function (Transaminase >2 times the upper limit of normal). 19. Uncontrolled microvascular (diabetic) complications, such as current proliferative diabetic retinopathy or macular edema, known diabetic nephropathy (other than microalbuminuria with normal creatinine) or neuropathy requiring drug treatment. 20. Active gastroparesis requiring current medical therapy. 21. Uncontrolled adrenal disorder. 22. Uncontrolled thyroid disease. 23. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study. 24. Known bleeding diathesis or dyscrasia. 25. Known allergy to medical adhesives, components of the insulin pump insertion set or continuous glucose monitor sensor. 26. Subjects with basal rates less than 0.01U/hr. 27. Subjects who are sexually active and able to become pregnant and not using an acceptable method of birth control. ON USE OF OTHER DRUGS OR 1. Use of anti-diabetic agents other than continuous subcutaneous insulin infusion (CSII) including long-acting insulin, intermediate-acting insulin, metformin, sulfonylureas, meglitinides, thiazolidinediones, dipeptidyl peptidase 4 (DPP-4 ) inhibitors, glucagon like peptide 1 agonists, colesevelam, quick release bromocriptine, sodium-glucose linked transporter (SGLT-2) inhibitors and alpha-glucosidase inhibitors. 2. Acetaminophen will not be allowed while the continuous glucose monitor is in use. 3. Medications that block symptoms of hypoglycemia, including but not limited to beta blockers. 4. Oral steroids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study. 5. Use of drugs that stimulate gastrointestinal motility (e.g. metoclopramide). 6. Orally administered medications (prescription and non-prescription) which require rapid onset as a critical determinant of effectiveness must be given at least 1 hour prior to or 2 hours after the Pramlintide injection and that subjects who require such medications be excluded if the medication must be given less than 1 hour prior to or 2 hours after the pramlintide dose. 7. Medications known to interfere with hypoglycemic symptoms including but not limited to beta blockers, clonidine, reserpine, and guanethidine